MARKET

TLSA

TLSA

Tiziana Life Sciences Ltd Com
NASDAQ
1.310
+0.080
+6.50%
After Hours: 1.310 0 0.00% 17:24 07/02 EDT
OPEN
1.250
PREV CLOSE
1.230
HIGH
1.320
LOW
1.250
VOLUME
161.19K
TURNOVER
--
52 WEEK HIGH
2.600
52 WEEK LOW
1.040
MARKET CAP
166.71M
P/E (TTM)
-8.4082
1D
5D
1M
3M
1Y
5Y
1D
RIVN Stock Pops as Rivian Raises Delivery Outlook
Barchart · 20h ago
Weekly Report: what happened at TLSA last week (0622-0626)?
Weekly Report · 4d ago
Tiziana Life Sciences Completes Enrollment in Phase 2 INFORM-MS Trial for Intranasal Foralumab
TipRanks · 06/25 11:31
BRIEF-Tiziana Announces Last Patient Successfully Dosed In Its Phase 2 Inform-MS Trial
Reuters · 06/25 11:22
Tiziana Life Sciences doses last patient in intranasal foralumab trial
TipRanks · 06/25 11:20
Tiziana Announces Last Patient In Ongoing Phase 2a Clinical Trial Receives First Dose Of Intranasal Foralumab For Treatment Of Non-Active Secondary Progressive Multiple Sclerosis; Topline Data Expected In Late Q3/Early Q4 Of 2026
Benzinga · 06/25 11:03
Tiziana Life Sciences completes first dosing in Phase 2 INFORM-MS trial of intranasal foralumab in secondary progressive MS
PUBT · 06/25 11:00
TIZIANA LIFE SCIENCES - TOPLINE DATA FROM INFORM-MS TRIAL EXPECTED LATE Q3 OR EARLY Q4 2026
Reuters · 06/25 11:00
More
About TLSA
Tiziana Life Sciences Ltd. is a biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Its clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer’s, and Amyotrophic lateral sclerosis. Its lead immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer’s and other CNS indications. Its Anti-IL-6R mAb (TZLS-501), a fully human mAb, binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune and cancer, reducing circulating levels of the IL-6 cytokine. Milciclib is a potent, small molecule inhibitor of multiple cyclin-dependent kinases (CDKs), tropomycinreceptor kinases and Src family kinases controlling cell growth and malignant progression of cancer.

Webull offers Tiziana Life Sciences Ltd - ADR stock information, including NASDAQ: TLSA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TLSA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TLSA stock methods without spending real money on the virtual paper trading platform.